



Clinical trial results:

Study VEG108844, A study of Pazopanib versus Sunitinib in the Treatment of Subjects with Locally Advanced and/or Metastatic Renal Cell Carcinoma

Summary

EudraCT number	2008-002102-19
Trial protocol	IE GB ES SE NL IT DE
Global end of trial date	24 March 2021

Results information

Result version number	v1
This version publication date	06 April 2022
First version publication date	06 April 2022

Trial information

Trial identification

Sponsor protocol code	108844
-----------------------	--------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00720941
WHO universal trial number (UTN)	-
Other trial identifiers	Novartis: CPZP034A2301, GlaxoSmithKline: VEG108844

Notes:

Sponsors

Sponsor organisation name	Novartis Pharma AG
Sponsor organisation address	Novartis Campus, Basel, Switzerland,
Public contact	Clinical Disclosure Office, Novartis Pharma AG, 41 613241111, Novartis.email@Novartis.com
Scientific contact	Clinical Disclosure Office, Novartis Pharma AG, 41 613241111, Novartis.email@Novartis.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	24 March 2021
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	24 March 2021
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective was to compare progression-free survival of subjects treated with pazopanib to those treated with sunitinib.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	14 August 2008
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 51
Country: Number of subjects enrolled	Canada: 46
Country: Number of subjects enrolled	China: 209
Country: Number of subjects enrolled	Germany: 55
Country: Number of subjects enrolled	Ireland: 17
Country: Number of subjects enrolled	Italy: 36
Country: Number of subjects enrolled	Japan: 61
Country: Number of subjects enrolled	Korea, Republic of: 68
Country: Number of subjects enrolled	Netherlands: 19
Country: Number of subjects enrolled	Spain: 41
Country: Number of subjects enrolled	Sweden: 16
Country: Number of subjects enrolled	Taiwan: 29
Country: Number of subjects enrolled	United Kingdom: 126
Country: Number of subjects enrolled	United States: 336
Worldwide total number of subjects	1110
EEA total number of subjects	184

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	676
From 65 to 84 years	428
85 years and over	6

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Participants were stratified based on Karnofsky Performance Scale scores (70 or 80; 90 or 100), Baseline levels of lactate dehydrogenase (>1.5 versus ≤ 1.5 times the upper limit of normal [ULN]), and previous nephrectomy (yes versus no) and were randomized in a 1:1 ratio to receive either pazopanib or sunitinib.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

Arm title	Pazopanib 800 mg
------------------	------------------

Arm description:

Participants were administered pazopanib 800 milligrams (mg) (2 x 400 mg tablets) orally once daily (OD) continuously. Pazopanib was to be taken at least one hour before or at least two hours after a meal. Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.

Arm type	Experimental
Investigational medicinal product name	Pazopanib
Investigational medicinal product code	
Other name	GW786034
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

800 mg (2 x 400 mg tablets or 4 x 200 mg tablets) administered orally once daily (continuously) at least 1 hour before or at least 2 hours after a meal.

Arm title	Sunitinib 50 mg
------------------	-----------------

Arm description:

Participants were administered sunitinib 50 mg orally once daily in 6-week cycles (4 weeks of treatment, followed by 2 weeks without treatment). Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.

Arm type	Active comparator
Investigational medicinal product name	Sunitinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

50 mg administered in 6-week cycles orally once daily with or without food, for 4 weeks of treatment followed by 2 weeks without treatment.

Number of subjects in period 1	Pazopanib 800 mg	Sunitinib 50 mg
Started	557	553
Safety Population	554	548
Completed	485	481
Not completed	72	72
Physician decision	14	12
Consent withdrawn by subject	29	36
Lost to follow-up	20	15
Protocol deviation	1	2
Transitioned to another mechanism of cont. therapy	8	7

Baseline characteristics

Reporting groups

Reporting group title	Pazopanib 800 mg
-----------------------	------------------

Reporting group description:

Participants were administered pazopanib 800 milligrams (mg) (2 x 400 mg tablets) orally once daily (OD) continuously. Pazopanib was to be taken at least one hour before or at least two hours after a meal. Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.

Reporting group title	Sunitinib 50 mg
-----------------------	-----------------

Reporting group description:

Participants were administered sunitinib 50 mg orally once daily in 6-week cycles (4 weeks of treatment, followed by 2 weeks without treatment). Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.

Reporting group values	Pazopanib 800 mg	Sunitinib 50 mg	Total
Number of subjects	557	553	1110
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	344	332	676
From 65-84 years	208	220	428
85 years and over	5	1	6
Gender categorical			
Units: Subjects			
Female	159	138	297
Male	398	415	813
Race/Ethnicity, Customized			
Units: Subjects			
White	349	358	707
Asian	194	188	382
African American/African Heritage	10	5	15
American Indian or Alaska Native	3	0	3
American Indian or Alaska Native & White	0	1	1
Unkonwn	1	1	2
AgeContinuous			
Units: Years			
arithmetic mean	60.9	61.2	
standard deviation	± 10.89	± 10.98	-

End points

End points reporting groups

Reporting group title	Pazopanib 800 mg
Reporting group description: Participants were administered pazopanib 800 milligrams (mg) (2 x 400 mg tablets) orally once daily (OD) continuously. Pazopanib was to be taken at least one hour before or at least two hours after a meal. Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.	
Reporting group title	Sunitinib 50 mg
Reporting group description: Participants were administered sunitinib 50 mg orally once daily in 6-week cycles (4 weeks of treatment, followed by 2 weeks without treatment). Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.	

Primary: Progression-free Survival (PFS)

End point title	Progression-free Survival (PFS)
End point description: PFS was defined as the interval between the date of randomization and the earliest date of progressive disease (PD), as defined by the Independent Review Committee (IRC), or death due to any cause. The IRC defined PD per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1. Per RECIST, PD is defined as a $\geq 20\%$ increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of ≥ 1 new lesion.	
End point type	Primary
End point timeframe: From randomization until the earliest date of disease progression or date of death from any cause, whichever comes first, assessed up to approximately 45 months	

End point values	Pazopanib 800 mg	Sunitinib 50 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	557	553		
Units: Months				
median (confidence interval 95%)	8.4 (8.3 to 10.9)	9.5 (8.3 to 11.1)		

Statistical analyses

Statistical analysis title	Progression-free Survival (PFS)
Comparison groups	Pazopanib 800 mg v Sunitinib 50 mg

Number of subjects included in analysis	1110
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[1]
Parameter estimate	Hazard ratio (HR)
Point estimate	1.0466
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.8982
upper limit	1.2195

Notes:

[1] - Non-inferiority is defined as excluding a difference of greater than 25% in the hazards. The upper limit of the 95% confidence interval must be <1.25.

Secondary: Overall Survival

End point title	Overall Survival
End point description:	
Overall survival was defined as the time from randomization until death due to any cause.	
End point type	Secondary
End point timeframe:	
From randomization until date of death from any cause, assessed up to approximately 151 months	

End point values	Pazopanib 800 mg	Sunitinib 50 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	557	553		
Units: Months				
median (confidence interval 95%)	28.3 (26.0 to 35.5)	29.1 (25.4 to 33.1)		

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Response Rate (ORR) as assessed by independent review

End point title	Overall Response Rate (ORR) as assessed by independent review
End point description:	
The number of participants with evidence of Complete Response (CR) (the disappearance of all target and non-target lesions), Partial Response (PR) (at least a 30% decrease in the sum of the longest diameters [LD] of target lesions, taking as a reference the Baseline sum LD), Stable Disease (small changes that do not meet previously given criteria, taking as reference the smallest sum LD since the treatment started), or Progressive Disease (a $\geq 20\%$ increase in the sum of the LD of target lesions, taking as a reference the smallest sum LD recorded since the treatment started) was evaluated by an independent review per RECIST, Version 1.	
End point type	Secondary
End point timeframe:	
From randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to approximately 151 months	

End point values	Pazopanib 800 mg	Sunitinib 50 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	557	553		
Units: Participants				
Complete Response	1	3		
Partial Response	170	134		
Stable Disease	216	242		
Progressive Disease	97	105		
Unknown	73	69		

Statistical analyses

No statistical analyses for this end point

Secondary: Time to Response

End point title	Time to Response
End point description:	
Time to response was defined as the time from the start of treatment until the first documented evidence of CR (the disappearance of all target and non-target lesions) or PR (at least a 30% decrease in the sum of the LD of target lesions, taking as a reference the Baseline sum LD), whichever comes first. CR and PR were evaluated by an independent review per RECIST, Version 1.	
End point type	Secondary
End point timeframe:	
From randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to approximately 151 months	

End point values	Pazopanib 800 mg	Sunitinib 50 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	171	137		
Units: Weeks				
median (confidence interval 95%)	11.9 (11.3 to 12.1)	17.4 (12.7 to 18.0)		

Statistical analyses

No statistical analyses for this end point

Secondary: Duration of Response (DOR)

End point title	Duration of Response (DOR)
-----------------	----------------------------

End point description:

DOR was defined as the time from the first documented evidence of response (CR or PR) until the first documented sign of disease progression (a $\geq 20\%$ increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of ≥ 1 new lesion) or death, if sooner. CR=the disappearance of all target and non-target lesions. PR=at least a 30% decrease in the sum of the LD of target lesions, taking as a reference the Baseline sum LD.

End point type	Secondary
----------------	-----------

End point timeframe:

From the date of the first documented response (CR or PR) to the date of first documented progression or death due to any cause, assessed up to approximately 151 months

End point values	Pazopanib 800 mg	Sunitinib 50 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	171	137		
Units: Months				
median (confidence interval 95%)	13.8 (12.2 to 16.4)	18.0 (14.3 to 22.1)		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with Adverse Events

End point title	Number of participants with Adverse Events
-----------------	--

End point description:

The distribution of adverse events was done via the analysis of frequencies for Adverse Event (AEs) and Serious Adverse Event (SAEs), through the monitoring of relevant clinical and laboratory safety parameters.

End point type	Secondary
----------------	-----------

End point timeframe:

From study treatment start date till 28 days safety follow-up, assessed up to approximately 152 months

End point values	Pazopanib 800 mg	Sunitinib 50 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	554	548		
Units: Participants				
Adverse Events (AEs)	551	535		
Serious Adverse Events (SAEs)	242	227		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT-F) scale scores at Day 28 of Cycles 1-4

End point title	Change from Baseline in Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT-F) scale scores at Day 28 of Cycles 1-4
-----------------	---

End point description:

FACIT Fatigue Subscale is a short, 13-item, easy to administer tool that measures an individual's level of fatigue during their usual daily activities over the past week. The level of fatigue is measured on a four point Likert scale (4 = not at all fatigued to 0 = very much fatigued). The total score range is from 0-52. The higher the score, the lower the fatigue level.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (predose), Day 28 of Cycles 1-4 (average of Weeks 4, 10, 16, and 22, respectively)

End point values	Pazopanib 800 mg	Sunitinib 50 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	353	375		
Units: Scores on a scale				
arithmetic mean (standard deviation)				
Week 4 (n=353,375)	-5.3 (± 11.00)	-6.7 (± 10.93)		
Week 10 (n=293,330)	-4.0 (± 10.28)	-6.3 (± 10.65)		
Week 16 (n=273,280)	-3.8 (± 10.13)	-6.9 (± 11.16)		
Week 22 (n=227,240)	-2.9 (± 9.77)	-6.5 (± 10.51)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in the FACT-Kidney Symptom Index-19 (FKSI-19) scale disease-related symptoms-physical (DRS-P) domain score at Day 28 of Cycles 1-4

End point title	Change from Baseline in the FACT-Kidney Symptom Index-19 (FKSI-19) scale disease-related symptoms-physical (DRS-P) domain score at Day 28 of Cycles 1-4
-----------------	---

End point description:

Health outcome and quality of life as measured by NCCN/FACT FKSI-19 questionnaire. The FKSI-19 is a disease-specific instrument that measures disease and treatment-related symptoms specifically in renal cancer patients in 4 domains (Disease-Related Symptoms – Physical (FKSI-DRS-P), Disease-Related Symptoms – Emotional (FKSI-DRS-E), Treatment Side-Effects (FKSI-TSE), Function/Well-Being (FKSI-FWB)) experienced in the past 7 days. Participants are asked to respond to a total of 19 questions regarding symptoms, side effects, and well being by using a 5-point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much; possible total score of 0 to 76). A negative mean indicates a worsening of condition.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (predose), Day 28 of Cycles 1-4 (average of Weeks 4, 10, 16, and 22, respectively)

End point values	Pazopanib 800 mg	Sunitinib 50 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	358	378		
Units: Scores on a scale				
arithmetic mean (standard deviation)				
Week 4 (n=358,378)	-2.9 (± 6.39)	-3.9 (± 6.87)		
Week 10 (n=296,336)	-2.3 (± 6.69)	-3.2 (± 6.76)		
Week 16 (n=269,283)	-2.6 (± 6.70)	-3.2 (± 6.61)		
Week 22 (n=224,238)	-1.3 (± 6.29)	-2.7 (± 6.42)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in the FACT-Kidney Symptom Index-19 (FKSI-19) scale disease related symptoms-emotional (DRS-E) domain score at Day 28 of Cycles 1-4

End point title	Change from Baseline in the FACT-Kidney Symptom Index-19 (FKSI-19) scale disease related symptoms-emotional (DRS-E) domain score at Day 28 of Cycles 1-4
-----------------	--

End point description:

Health outcome and quality of life as measured by NCCN/FACT FKSI-19 questionnaire. The FKSI-19 is a disease-specific instrument that measures disease and treatment-related symptoms specifically in renal cancer patients in 4 domains (Disease-Related Symptoms – Physical (FKSI-DRS-P), Disease-Related Symptoms – Emotional (FKSI-DRS-E), Treatment Side-Effects (FKSI-TSE), Function/Well-Being (FKSI-FWB)) experienced in the past 7 days. Participants are asked to respond to a total of 19 questions regarding symptoms, side effects, and well being by using a 5-point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much; possible total score of 0 to 76). A negative mean indicates a worsening of condition.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (predose), Day 28 of Cycles 1-4 (average of Weeks 4, 10, 16, and 22, respectively)

End point values	Pazopanib 800 mg	Sunitinib 50 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	344	367		
Units: Scores on a scale				
arithmetic mean (standard deviation)				
Week 4 (n=344,367)	0.3 (± 1.31)	0.4 (± 1.22)		
Week 10 (n=287,329)	0.4 (± 1.33)	0.5 (± 1.32)		
Week 16 (n=260,277)	0.5 (± 1.39)	0.6 (± 1.30)		
Week 22 (n=220,233)	0.6 (± 1.27)	0.6 (± 1.20)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in the FACT-Kidney Symptom Index-19 (FKSI-19) scale treatment side effects (TSE) domain score at Day 28 of Cycles 1-4

End point title	Change from Baseline in the FACT-Kidney Symptom Index-19 (FKSI-19) scale treatment side effects (TSE) domain score at Day 28 of Cycles 1-4
-----------------	--

End point description:

Health outcome and quality of life as measured by NCCN/FACT FKSI-19 questionnaire. The FKSI-19 is a disease-specific instrument that measures disease and treatment-related symptoms specifically in renal cancer patients in 4 domains (Disease-Related Symptoms – Physical (FKSI-DRS-P), Disease-Related Symptoms – Emotional (FKSI-DRS-E), Treatment Side-Effects (FKSI-TSE), Function/Well-Being (FKSI-FWB)) experienced in the past 7 days. Participants are asked to respond to a total of 19 questions regarding symptoms, side effects, and well being by using a 5-point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much; possible total score of 0 to 76). A negative mean indicates a worsening of condition.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (predose), Day 28 of Cycles 1-4 (average of Weeks 4, 10, 16, and 22, respectively)

End point values	Pazopanib 800 mg	Sunitinib 50 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	326	350		
Units: Scores on a scale				
arithmetic mean (standard deviation)				
Week 4 (n=326,350)	-1.5 (± 2.45)	-2.0 (± 2.35)		
Week 10 (n=267,305)	-1.9 (± 2.66)	-2.4 (± 2.62)		
Week 16 (n=244,254)	-2.1 (± 2.79)	-2.8 (± 2.46)		
Week 22 (n=201,218)	-2.4 (± 2.75)	-2.4 (± 2.33)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in the FACT-Kidney Symptom Index-19 (FKSI-19) scale functional well being (FWB) domain score at Day 28 of Cycles 1-4

End point title	Change from Baseline in the FACT-Kidney Symptom Index-19 (FKSI-19) scale functional well being (FWB) domain score at Day 28 of Cycles 1-4
-----------------	---

End point description:

Health outcome and quality of life as measured by NCCN/FACT FKSI-19 questionnaire. The FKSI-19 is a disease-specific instrument that measures disease and treatment-related symptoms specifically in renal cancer patients in 4 domains (Disease-Related Symptoms – Physical (FKSI-DRS-P), Disease-Related Symptoms – Emotional (FKSI-DRS-E), Treatment Side-Effects (FKSI-TSE), Function/Well-Being (FKSI-FWB)) experienced in the past 7 days. Participants are asked to respond to a total of 19 questions regarding symptoms, side effects, and well being by using a 5-point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much; possible total score of 0 to 76). A negative mean indicates a worsening of condition.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (predose), Day 28 of Cycles 1-4 (average of Weeks 4, 10, 16, and 22, respectively)

End point values	Pazopanib 800 mg	Sunitinib 50 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	357	378		
Units: Scores on a scale				
arithmetic mean (standard deviation)				
Week 4 (n=357,378)	-1.0 (± 4.01)	-1.3 (± 3.63)		
Week 10 (n=298,331)	-0.6 (± 4.00)	-1.1 (± 3.94)		
Week 16 (n=267,278)	-0.8 (± 4.08)	-1.0 (± 3.96)		
Week 22 (n=228,234)	-0.7 (± 3.93)	-1.0 (± 3.82)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in the FACT-Kidney Symptom Index-19 (FKSI-19) scale total score at Day 28 of Cycles 1-4

End point title	Change from Baseline in the FACT-Kidney Symptom Index-19 (FKSI-19) scale total score at Day 28 of Cycles 1-4
-----------------	--

End point description:

Health outcome and quality of life as measured by NCCN/FACT FKSI-19 questionnaire. The FKSI-19 is a disease-specific instrument that measures disease and treatment-related symptoms specifically in renal cancer patients in 4 domains (Disease-Related Symptoms – Physical (FKSI-DRS-P), Disease-Related Symptoms – Emotional (FKSI-DRS-E), Treatment Side-Effects (FKSI-TSE), Function/Well-Being (FKSI-FWB)) experienced in the past 7 days. Participants are asked to respond to a total of 19 questions regarding symptoms, side effects, and well being by using a 5-point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much; possible total score of 0 to 76). A negative mean indicates a worsening of condition.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (predose), Day 28 of Cycles 1-4 (average of Weeks 4, 10, 16, and 22, respectively)

End point values	Pazopanib 800 mg	Sunitinib 50 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	358	379		
Units: Scores on a scale				
arithmetic mean (standard deviation)				
Week 4 (n=358,379)	-5.0 (± 10.82)	-6.6 (± 10.55)		
Week 10 (n=296,337)	-4.2 (± 10.95)	-6.3 (± 11.21)		
Week 16 (n=267,284)	-4.8 (± 11.13)	-6.3 (± 10.67)		
Week 22 (n=225,238)	-3.7 (± 10.49)	-5.5 (± 10.13)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in the Supplementary Quality of Life Questions (SQLQ) scale worst soreness scores at Day 28 of Cycles 1-4

End point title	Change from Baseline in the Supplementary Quality of Life Questions (SQLQ) scale worst soreness scores at Day 28 of Cycles 1-4
-----------------	--

End point description:

The SQLQ scale consists of 5 items that assess the worst mouth and throat, hand, and foot soreness, as well as limitations due to mouth/throat and foot soreness. Participants were asked to assess their worst mouth/throat, hand, and foot soreness by answering the question of "In the past 4 weeks, what was your worst mouth/throat, hand, and foot soreness?" by using the following 4-point scale: 0, I never had any soreness; 1, I had a little bit of soreness; 2, I had quite a lot of soreness; 3, I had severe soreness. A positive mean change from Baseline represents a worsening of condition.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (predose), Day 28 of Cycles 1-4 (average of Weeks 4, 10, 16, and 22, respectively)

End point values	Pazopanib 800 mg	Sunitinib 50 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	202	184		
Units: Scores on a scale				
arithmetic mean (standard deviation)				
Mouth and Throat Soreness, Week 4 (n=202,180)	0.4 (± 0.87)	1.0 (± 0.99)		
Mouth and Throat Soreness, Week 10 (n=164,155)	0.4 (± 0.88)	0.9 (± 0.99)		
Mouth and Throat Soreness, Week 16 (n=137,138)	0.3 (± 0.73)	0.8 (± 0.89)		
Mouth and Throat Soreness, Week 22 (n=120,117)	0.2 (± 0.75)	0.8 (± 0.81)		
Hand Soreness, Week 4 (n=200,184)	0.2 (± 0.71)	0.3 (± 0.72)		
Hand Soreness, Week 10 (n=164,153)	0.3 (± 0.84)	0.7 (± 0.85)		
Hand Soreness, Week 16 (n=139,136)	0.4 (± 0.76)	0.6 (± 0.80)		
Hand Soreness, Week 22 (n=123,115)	0.3 (± 0.69)	0.6 (± 0.82)		
Foot Soreness, Week 4 (n=199,182)	0.2 (± 0.86)	0.4 (± 0.80)		

Foot Soreness, Week 10 (n=163,153)	0.3 (± 1.00)	0.6 (± 0.99)		
Foot Soreness, Week 16 (n=140,136)	0.3 (± 1.07)	0.8 (± 0.99)		
Foot Soreness, Week 22 (n=123,116)	0.3 (± 1.04)	0.9 (± 0.96)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in the Supplementary Quality of Life Questions (SQLQ) limitations due to mouth and throat soreness score at Day 28 of Cycles 1-4

End point title	Change from Baseline in the Supplementary Quality of Life Questions (SQLQ) limitations due to mouth and throat soreness score at Day 28 of Cycles 1-4
-----------------	---

End point description:

The SQLQ consists of 5 items assessing the worst mouth/throat, hand, and foot soreness, and limitations due to mouth/throat and foot soreness. Participants assessed the limitations caused by their mouth/throat soreness by answering the question of "In the past 4 weeks, how much did your worst mouth/throat soreness limit you in the following activities: swallowing/eating/drinking/talking/sleeping" by using the following 4-point scale: 0, not limited; 1, limited a little; 2, limited a lot; 3, unable to do. The overall limitation score (15=best; 0=worst), based on the individual scores for the 5 activities, is derived as follows: the actual scores were rescored by subtracting the actual score from "3" for each of the 5 categories. A high score indicates less limitation. Change from Baseline was calculated as the assessment week value minus the Baseline value. A negative mean change from Baseline represents a worsening of condition.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (predose), Day 28 of Cycles 1-4 (average of Weeks 4, 10, 16, and 22, respectively)

End point values	Pazopanib 800 mg	Sunitinib 50 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	177	170		
Units: Scores on a scale				
arithmetic mean (standard deviation)				
Week 4 (n=177,170)	-0.9 (± 2.09)	-1.8 (± 2.91)		
Week 10 (n=144,137)	-0.9 (± 1.91)	-1.8 (± 3.06)		
Week 16 (n=125,122)	-0.6 (± 1.56)	-1.3 (± 2.30)		
Week 22 (n=111,107)	-0.4 (± 1.67)	-1.4 (± 1.85)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in the Supplementary Quality of Life Questions (SQLQ) Limitations Due to Foot Soreness Scores at Day 28 of Cycles 1-4

End point title	Change From Baseline in the Supplementary Quality of Life Questions (SQLQ) Limitations Due to Foot Soreness Scores at Day 28 of Cycles 1-4
-----------------	--

End point description:

The SQLQ consists of 5 items assessing the worst mouth/throat, hand, and foot soreness, and limitations due to mouth/throat and foot soreness. Participants assessed the limitations caused by their foot soreness by answering the question of "In the past 4 weeks, how much did your worst foot soreness limit you in each of the following activities: standing/walking/climbing stairs/sleeping/ability to do usual activities" by using the following 4-point scale: 0, not limited; 1, limited a little; 2, limited a lot; 3, unable to do. The overall limitation score (15=best; 0=worst), based on the individual scores for the 5 activities, is derived as follows: the actual scores were rescored by subtracting the actual score from "3" for each of the 5 categories. A high score indicates less limitation. Change from Baseline was calculated as the assessment week value minus the Baseline value. A negative mean change from Baseline represents a worsening of condition.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (predose), Day 28 of Cycles 1-4 (average of Weeks 4, 10, 16, and 22, respectively)

End point values	Pazopanib 800 mg	Sunitinib 50 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	170	163		
Units: Scores on a scale				
arithmetic mean (standard deviation)				
Week 4 (n=170,163)	-0.6 (± 2.94)	-1.0 (± 2.94)		
Week 10 (n=133,136)	-1.1 (± 3.02)	-1.5 (± 3.76)		
Week 16 (n=114,126)	-1.2 (± 3.42)	-2.2 (± 3.50)		
Week 22 (n=105,108)	-1.3 (± 3.25)	-2.1 (± 3.52)		

Statistical analyses

No statistical analyses for this end point

Secondary: Summary of Analysis for the Cancer Treatment Satisfaction Questionnaire (CTSQ) Score at Day 28 of Cycles 1-4

End point title	Summary of Analysis for the Cancer Treatment Satisfaction Questionnaire (CTSQ) Score at Day 28 of Cycles 1-4
-----------------	--

End point description:

The CTSQ assesses 3 domains related to the participant's satisfaction with cancer therapy: Expectations of Therapy (ET), Feelings about Side Effects (FSE), and Satisfaction with Therapy (SWT). Participants shared their thoughts on their cancer therapy (9 questions), their satisfaction with their most recently administered cancer therapy (6 questions), and if they would take the same cancer therapy if given the choice to do so again. All questions were assessed on a 5-point scale; 1, never; 5, always. Scores were averaged and transformed to a 0-100 scale; higher scores represent better treatment satisfaction.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 28 of Cycles 1-4 (average of Weeks 4, 10, 16, and 22, respectively)

End point values	Pazopanib 800 mg	Sunitinib 50 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	383	386		
Units: Scores on a scale				
arithmetic mean (standard deviation)				
ET, Week 4 (n=383,386)	71.7 (± 22.13)	71.3 (± 22.38)		
ET, Week 10 (n=321,346)	73.4 (± 21.62)	73.4 (± 19.37)		
ET, Week 16 (n=296,293)	73.9 (± 21.56)	72.9 (± 21.43)		
ET, Week 22 (n=250,250)	73.0 (± 21.40)	73.4 (± 20.43)		
FSE, Week 4 (n=340,360)	66.3 (± 24.00)	58.5 (± 23.59)		
FSE, Week 10 (n=298,323)	66.0 (± 23.09)	56.0 (± 22.23)		
FSE, Week 16 (n=274,277)	65.0 (± 23.01)	56.6 (± 22.02)		
FSE, Week 22 (n=235, 232)	67.1 (± 22.62)	57.8 (± 21.28)		
SWT, Week 4 (n=355,374)	80.9 (± 15.49)	79.0 (± 15.23)		
SWT, Week 10 (n=309,336)	84.5 (± 13.74)	80.4 (± 15.15)		
SWT, Week 16 (n=287,284)	85.3 (± 14.77)	80.5 (± 15.08)		
SWT, Week 22 (n=241,240)	85.4 (± 13.48)	81.4 (± 15.04)		

Statistical analyses

No statistical analyses for this end point

Secondary: Mean Number of Non-study Medical Visits, Telephone Consultations, Hospital Days, and Emergency Room (ER) Visits Per 30 Days Through Week 24

End point title	Mean Number of Non-study Medical Visits, Telephone Consultations, Hospital Days, and Emergency Room (ER) Visits Per 30 Days Through Week 24
-----------------	---

End point description:

Non-study medical visits were defined as the sum of primary care physician visits, nurse practitioner/physician's assistant/nurse visits, and medical or surgical specialist visits. Days hospitalized were defined as the sum of days in the general ward and days in intensive care. The number of telephone consultations and ER visits was assessed via individual questions on the electronic Case Report Form. The endpoint was totaled through Week 24, divided by the number of days on treatment for each participant, then multiplied by 30 days to get the number of visits per 30 days.

End point type	Secondary
----------------	-----------

End point timeframe:

From Day 1 up to Week 24

End point values	Pazopanib 800 mg	Sunitinib 50 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	429	432		
Units: events per 30 days				
arithmetic mean (standard deviation)				
Non-Study Medical Visits	0.726 (± 1.472)	0.779 (± 1.690)		
Telephone Consultations	0.279 (± 0.718)	0.312 (± 0.656)		

Hospital Days	0.402 (\pm 2.273)	0.562 (\pm 2.187)		
ER Visits	0.037 (\pm 0.156)	0.067 (\pm 0.195)		

Statistical analyses

No statistical analyses for this end point

Secondary: Mean Number of Laboratory Visits, Radiology Visits, Home Healthcare Visits, and Medical Procedures at Day 28 of Cycles 1-4

End point title	Mean Number of Laboratory Visits, Radiology Visits, Home Healthcare Visits, and Medical Procedures at Day 28 of Cycles 1-4
-----------------	--

End point description:

The number of non-study laboratory visits (NSLVs), non-study radiology visits (NSRVs), and home healthcare visits (HHVs) were each collected as a single question on the eCRF. The number of non-study medical or surgical procedures (MSPs) was defined as the sum of procedures performed at outpatient or physician clinics, as well as those performed during any inpatient hospitalization.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 28 of Cycles 1-4 (average of Weeks 4, 10, 16, and 22, respectively)

End point values	Pazopanib 800 mg	Sunitinib 50 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	429	432		
Units: visits				
arithmetic mean (standard deviation)				
NSLV, Cycle 1 (n=417,414)	0.3 (\pm 1.25)	0.3 (\pm 1.14)		
NSLV, Cycle 2 (n=345,363)	0.3 (\pm 0.97)	0.4 (\pm 1.35)		
NSLV, Cycle 3 (n=299,304)	0.2 (\pm 0.67)	0.2 (\pm 0.58)		
NSLV, Cycle 4 (n=265,254)	0.1 (\pm 0.49)	0.1 (\pm 0.47)		
NSRV, Cycle 1 (n=419,414)	0.1 (\pm 0.44)	0.1 (\pm 0.56)		
NSRV, Cycle 2 (n=348,364)	0.1 (\pm 0.36)	0.1 (\pm 0.88)		
NSRV, Cycle 3 (n=299,305)	0.0 (\pm 0.28)	0.1 (\pm 0.33)		
NSRV, Cycle 4 (n=266,255)	0.0 (\pm 0.24)	0.1 (\pm 0.46)		
HHV, Cycle 1 (n=418,411)	0.0 (\pm 0.44)	0.1 (\pm 0.77)		
HHV, Cycle 2 (n=343,363)	0.1 (\pm 0.52)	0.1 (\pm 0.64)		
HHV, Cycle 3 (n=298,304)	0.1 (\pm 0.72)	0.0 (\pm 0.37)		
HHV, Cycle 4 (n=265,254)	0.0 (\pm 0.49)	0.1 (\pm 1.77)		
NSP, Cycle 1 (n=417,413)	0.2 (\pm 0.69)	0.3 (\pm 2.52)		
NSP, Cycle 2 (n=344,363)	0.2 (\pm 0.68)	0.2 (\pm 1.17)		
NSP, Cycle 3 (n=298,304)	0.2 (\pm 0.60)	0.3 (\pm 1.98)		
NSP, Cycle 4 (n=266,254)	0.2 (\pm 0.85)	0.3 (\pm 1.73)		

Statistical analyses

No statistical analyses for this end point

Other pre-specified: All collected deaths

End point title	All collected deaths
-----------------	----------------------

End point description:

On treatment deaths were collected from FPFT up to 28 days after study drug discontinuation, for a maximum duration with Pazopanib of 129 months (study treatment with Pazopanib ranged from 0 to 128 months) and for a maximum duration with Sunitinib of 125 months (study treatment with Sunitinib ranged from 0 to 124 months).

Deaths post treatment survival follow up were collected after the on-treatment period, up to approximately 152 months. Patients who didn't die during the on-treatment period and had not stopped study participation at the time of data cut-off (end of study) were censored.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

up to 129 months (study treatment with Pazopanib), up to 125 months (study treatment with Sunitinib), up to approximately 152 months (study duration)

End point values	Pazopanib 800 mg	Sunitinib 50 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	335	334		
Units: Participants				
= < 28 days	25	22		
> 28 days	309	312		
Unknown	1	0		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse Events were collected from First Patient First Treatment (FPFT) till 28 days safety follow-up, assessed up to approximately 152 months

Adverse event reporting additional description:

Consistent with EudraCT disclosure specifications, Novartis has reported under the Serious adverse events field "number of deaths resulting from adverse events" all those deaths, resulting from serious adverse events that are deemed to be causally related to treatment by the investigator.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	24.1
--------------------	------

Reporting groups

Reporting group title	Sunitinib
-----------------------	-----------

Reporting group description:

Sunitinib

Reporting group title	Pazopanib
-----------------------	-----------

Reporting group description:

Pazopanib

Serious adverse events	Sunitinib	Pazopanib	
Total subjects affected by serious adverse events			
subjects affected / exposed	227 / 548 (41.42%)	242 / 554 (43.68%)	
number of deaths (all causes)	334	335	
number of deaths resulting from adverse events	8	3	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenocarcinoma of colon			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basal cell carcinoma			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Cancer pain			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholesteatoma			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon cancer			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endometrial cancer metastatic			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric cancer			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemangioblastoma			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lipoma			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung neoplasm malignant			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant melanoma			

subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to central nervous system			
subjects affected / exposed	2 / 548 (0.36%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Metastases to liver			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Metastases to lung			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastasis			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paraneoplastic syndrome			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parathyroid tumour benign			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cancer metastatic			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Signet-ring cell carcinoma			

subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of skin			
subjects affected / exposed	1 / 548 (0.18%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tumour associated fever			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tumour haemorrhage			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Tumour rupture			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Aortic thrombosis			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial rupture			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Deep vein thrombosis			
subjects affected / exposed	0 / 548 (0.00%)	2 / 554 (0.36%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dry gangrene			

subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Giant cell arteritis			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematoma			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertension			
subjects affected / exposed	6 / 548 (1.09%)	7 / 554 (1.26%)	
occurrences causally related to treatment / all	4 / 6	5 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypotension			
subjects affected / exposed	1 / 548 (0.18%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive crisis			
subjects affected / exposed	1 / 548 (0.18%)	2 / 554 (0.36%)	
occurrences causally related to treatment / all	1 / 1	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombosis			
subjects affected / exposed	1 / 548 (0.18%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orthostatic hypotension			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vena cava thrombosis			

subjects affected / exposed	1 / 548 (0.18%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	4 / 548 (0.73%)	2 / 554 (0.36%)	
occurrences causally related to treatment / all	1 / 4	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest pain			
subjects affected / exposed	0 / 548 (0.00%)	2 / 554 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Death			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Disease progression			
subjects affected / exposed	1 / 548 (0.18%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Fatigue			
subjects affected / exposed	12 / 548 (2.19%)	3 / 554 (0.54%)	
occurrences causally related to treatment / all	11 / 13	3 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
General physical health deterioration			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Impaired healing			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malaise			

subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-cardiac chest pain			
subjects affected / exposed	0 / 548 (0.00%)	2 / 554 (0.36%)	
occurrences causally related to treatment / all	0 / 0	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain			
subjects affected / exposed	3 / 548 (0.55%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumatoxis			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			
subjects affected / exposed	13 / 548 (2.37%)	5 / 554 (0.90%)	
occurrences causally related to treatment / all	7 / 13	3 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sudden death			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Bartholin's cyst			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Penile oedema			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic obstructive pulmonary disease			
subjects affected / exposed	2 / 548 (0.36%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	1 / 2	0 / 0	
Cough			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			
subjects affected / exposed	8 / 548 (1.46%)	5 / 554 (0.90%)	
occurrences causally related to treatment / all	3 / 9	1 / 5	
deaths causally related to treatment / all	0 / 1	0 / 0	
Epistaxis			
subjects affected / exposed	6 / 548 (1.09%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	4 / 6	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemoptysis			
subjects affected / exposed	2 / 548 (0.36%)	3 / 554 (0.54%)	
occurrences causally related to treatment / all	2 / 2	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemothorax			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Hiccups			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoxia			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngeal haemorrhage			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung infiltration			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural effusion			
subjects affected / exposed	11 / 548 (2.01%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	2 / 13	0 / 1	
deaths causally related to treatment / all	1 / 1	0 / 0	
Pleurisy			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pleuritic pain			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonitis			
subjects affected / exposed	2 / 548 (0.36%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	2 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax			

subjects affected / exposed	2 / 548 (0.36%)	2 / 554 (0.36%)	
occurrences causally related to treatment / all	1 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary artery thrombosis			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	7 / 548 (1.28%)	8 / 554 (1.44%)	
occurrences causally related to treatment / all	4 / 7	5 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary pain			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory failure			
subjects affected / exposed	2 / 548 (0.36%)	2 / 554 (0.36%)	
occurrences causally related to treatment / all	1 / 2	0 / 2	
deaths causally related to treatment / all	1 / 2	0 / 2	
Psychiatric disorders			
Anxiety			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Confusional state			
subjects affected / exposed	2 / 548 (0.36%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Emotional distress			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mental status changes			

subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sleep disorder			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	8 / 548 (1.46%)	35 / 554 (6.32%)	
occurrences causally related to treatment / all	6 / 8	36 / 37	
deaths causally related to treatment / all	0 / 0	0 / 0	
Amylase increased			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aspartate aminotransferase increased			
subjects affected / exposed	2 / 548 (0.36%)	17 / 554 (3.07%)	
occurrences causally related to treatment / all	2 / 2	16 / 17	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood bilirubin increased			
subjects affected / exposed	2 / 548 (0.36%)	2 / 554 (0.36%)	
occurrences causally related to treatment / all	1 / 2	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood calcium increased			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood creatine increased			

subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood creatine phosphokinase increased			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood creatinine increased			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood glucose decreased			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood magnesium decreased			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood potassium increased			
subjects affected / exposed	1 / 548 (0.18%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 2	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ejection fraction decreased			
subjects affected / exposed	1 / 548 (0.18%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	1 / 1	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrocardiogram QT prolonged			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gamma-glutamyltransferase increased			

subjects affected / exposed	0 / 548 (0.00%)	3 / 554 (0.54%)	
occurrences causally related to treatment / all	0 / 0	3 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemoglobin decreased			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic enzyme increased			
subjects affected / exposed	1 / 548 (0.18%)	6 / 554 (1.08%)	
occurrences causally related to treatment / all	1 / 1	6 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lipase increased			
subjects affected / exposed	4 / 548 (0.73%)	7 / 554 (1.26%)	
occurrences causally related to treatment / all	4 / 4	6 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver function test abnormal			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver function test increased			
subjects affected / exposed	0 / 548 (0.00%)	2 / 554 (0.36%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutrophil count decreased			
subjects affected / exposed	0 / 548 (0.00%)	2 / 554 (0.36%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Platelet count decreased			
subjects affected / exposed	9 / 548 (1.64%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	8 / 9	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Acetabulum fracture			

subjects affected / exposed	0 / 548 (0.00%)	2 / 554 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ankle fracture			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain herniation			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
Chemical poisoning			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Contusion			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Craniocerebral injury			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fall			
subjects affected / exposed	2 / 548 (0.36%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Femoral neck fracture			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femur fracture			

subjects affected / exposed	2 / 548 (0.36%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Humerus fracture			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ilium fracture			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple fractures			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Patella fracture			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tibia fracture			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	2 / 548 (0.36%)	3 / 554 (0.54%)	
occurrences causally related to treatment / all	1 / 2	2 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angina pectoris			
subjects affected / exposed	0 / 548 (0.00%)	2 / 554 (0.36%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angina unstable			

subjects affected / exposed	1 / 548 (0.18%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial fibrillation			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial thrombosis			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bradycardia			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure congestive			
subjects affected / exposed	4 / 548 (0.73%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	4 / 4	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiopulmonary failure			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Coronary artery stenosis			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Left ventricular dysfunction			
subjects affected / exposed	1 / 548 (0.18%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	1 / 1	0 / 0	
Myocardial infarction			

subjects affected / exposed	4 / 548 (0.73%)	3 / 554 (0.54%)	
occurrences causally related to treatment / all	4 / 4	2 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Palpitations			
subjects affected / exposed	0 / 548 (0.00%)	2 / 554 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericardial effusion			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus node dysfunction			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tachycardia			
subjects affected / exposed	0 / 548 (0.00%)	2 / 554 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Torsade de pointes			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Central nervous system haemorrhage			
subjects affected / exposed	1 / 548 (0.18%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebellar haemorrhage			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral haemorrhage			

subjects affected / exposed	1 / 548 (0.18%)	5 / 554 (0.90%)	
occurrences causally related to treatment / all	1 / 1	3 / 5	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cerebral infarction			
subjects affected / exposed	2 / 548 (0.36%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cerebral ischaemia			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral small vessel ischaemic disease			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrovascular accident			
subjects affected / exposed	0 / 548 (0.00%)	2 / 554 (0.36%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrovascular insufficiency			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dizziness			
subjects affected / exposed	1 / 548 (0.18%)	2 / 554 (0.36%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Encephalopathy			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhage intracranial			

subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
Haemorrhagic cerebral infarction			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Headache			
subjects affected / exposed	1 / 548 (0.18%)	2 / 554 (0.36%)	
occurrences causally related to treatment / all	0 / 1	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hemianaesthesia			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoaesthesia			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic stroke			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lethargy			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Loss of consciousness			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolic encephalopathy			

subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Motor dysfunction			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paraesthesia			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paraplegia			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Presyncope			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seizure			
subjects affected / exposed	3 / 548 (0.55%)	2 / 554 (0.36%)	
occurrences causally related to treatment / all	0 / 3	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal cord compression			
subjects affected / exposed	3 / 548 (0.55%)	4 / 554 (0.72%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subarachnoid haemorrhage			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syncope			

subjects affected / exposed	4 / 548 (0.73%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	2 / 4	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transient ischaemic attack			
subjects affected / exposed	1 / 548 (0.18%)	3 / 554 (0.54%)	
occurrences causally related to treatment / all	1 / 1	2 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tremor			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	9 / 548 (1.64%)	9 / 554 (1.62%)	
occurrences causally related to treatment / all	7 / 9	6 / 9	
deaths causally related to treatment / all	1 / 1	1 / 1	
Febrile neutropenia			
subjects affected / exposed	0 / 548 (0.00%)	2 / 554 (0.36%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune thrombocytopenia			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphopenia			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Microangiopathic haemolytic anaemia			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
Neutropenia			

subjects affected / exposed	7 / 548 (1.28%)	2 / 554 (0.36%)	
occurrences causally related to treatment / all	6 / 7	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polycythaemia			
subjects affected / exposed	0 / 548 (0.00%)	2 / 554 (0.36%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytopenia			
subjects affected / exposed	24 / 548 (4.38%)	4 / 554 (0.72%)	
occurrences causally related to treatment / all	25 / 25	4 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
Sudden hearing loss			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Retinal detachment			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal distension			
subjects affected / exposed	2 / 548 (0.36%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal hernia			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain			
subjects affected / exposed	5 / 548 (0.91%)	3 / 554 (0.54%)	
occurrences causally related to treatment / all	3 / 5	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	

Abdominal pain lower			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain upper			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal fistula			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal ulcer haemorrhage			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ascites			
subjects affected / exposed	1 / 548 (0.18%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis			
subjects affected / exposed	1 / 548 (0.18%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Constipation			
subjects affected / exposed	2 / 548 (0.36%)	2 / 554 (0.36%)	
occurrences causally related to treatment / all	1 / 2	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			
subjects affected / exposed	10 / 548 (1.82%)	5 / 554 (0.90%)	
occurrences causally related to treatment / all	9 / 11	5 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal ulcer			

subjects affected / exposed	1 / 548 (0.18%)	3 / 554 (0.54%)	
occurrences causally related to treatment / all	0 / 1	3 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal ulcer haemorrhage			
subjects affected / exposed	2 / 548 (0.36%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterocolitis			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erosive oesophagitis			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric fistula			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric haemorrhage			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis			
subjects affected / exposed	2 / 548 (0.36%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	1 / 2	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis erosive			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorder			

subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal haemorrhage			
subjects affected / exposed	2 / 548 (0.36%)	2 / 554 (0.36%)	
occurrences causally related to treatment / all	2 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glossodynia			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematemesis			
subjects affected / exposed	2 / 548 (0.36%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	1 / 3	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Haematochezia			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhoidal haemorrhage			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ileus			
subjects affected / exposed	0 / 548 (0.00%)	3 / 554 (0.54%)	
occurrences causally related to treatment / all	0 / 0	2 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia			
subjects affected / exposed	1 / 548 (0.18%)	2 / 554 (0.36%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal obstruction			

subjects affected / exposed	2 / 548 (0.36%)	2 / 554 (0.36%)	
occurrences causally related to treatment / all	1 / 2	0 / 2	
deaths causally related to treatment / all	1 / 2	0 / 0	
Large intestine polyp			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower gastrointestinal haemorrhage			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea			
subjects affected / exposed	7 / 548 (1.28%)	6 / 554 (1.08%)	
occurrences causally related to treatment / all	6 / 7	5 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophagitis ulcerative			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis			
subjects affected / exposed	2 / 548 (0.36%)	5 / 554 (0.90%)	
occurrences causally related to treatment / all	2 / 2	5 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis acute			
subjects affected / exposed	1 / 548 (0.18%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peptic ulcer			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal haemorrhage			

subjects affected / exposed	1 / 548 (0.18%)	2 / 554 (0.36%)	
occurrences causally related to treatment / all	1 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal haemorrhage			
subjects affected / exposed	0 / 548 (0.00%)	2 / 554 (0.36%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal obstruction			
subjects affected / exposed	2 / 548 (0.36%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stomatitis			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Swollen tongue			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper gastrointestinal haemorrhage			
subjects affected / exposed	1 / 548 (0.18%)	2 / 554 (0.36%)	
occurrences causally related to treatment / all	1 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	8 / 548 (1.46%)	7 / 554 (1.26%)	
occurrences causally related to treatment / all	7 / 9	3 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	1 / 548 (0.18%)	2 / 554 (0.36%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis acute			

subjects affected / exposed	2 / 548 (0.36%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 2	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholelithiasis			
subjects affected / exposed	1 / 548 (0.18%)	2 / 554 (0.36%)	
occurrences causally related to treatment / all	0 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug-induced liver injury			
subjects affected / exposed	2 / 548 (0.36%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	2 / 2	1 / 1	
deaths causally related to treatment / all	1 / 1	0 / 0	
Gallbladder rupture			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic function abnormal			
subjects affected / exposed	4 / 548 (0.73%)	7 / 554 (1.26%)	
occurrences causally related to treatment / all	4 / 4	7 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatotoxicity			
subjects affected / exposed	0 / 548 (0.00%)	8 / 554 (1.44%)	
occurrences causally related to treatment / all	0 / 0	8 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperbilirubinaemia			
subjects affected / exposed	2 / 548 (0.36%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Jaundice cholestatic			

subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Skin and subcutaneous tissue disorders			
Actinic keratosis			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angioedema			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Decubitus ulcer			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	0 / 548 (0.00%)	2 / 554 (0.36%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rash			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	9 / 548 (1.64%)	4 / 554 (0.72%)	
occurrences causally related to treatment / all	5 / 9	2 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematuria			
subjects affected / exposed	3 / 548 (0.55%)	2 / 554 (0.36%)	
occurrences causally related to treatment / all	1 / 4	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	

Nephrotic syndrome			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Proteinuria			
subjects affected / exposed	1 / 548 (0.18%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal failure			
subjects affected / exposed	4 / 548 (0.73%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	4 / 4	0 / 1	
deaths causally related to treatment / all	1 / 1	0 / 0	
Renal haemorrhage			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal impairment			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureteric obstruction			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary retention			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	2 / 548 (0.36%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue			

disorders			
Arthralgia			
subjects affected / exposed	0 / 548 (0.00%)	2 / 554 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Back pain			
subjects affected / exposed	5 / 548 (0.91%)	3 / 554 (0.54%)	
occurrences causally related to treatment / all	0 / 5	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bone pain			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fistula			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Flank pain			
subjects affected / exposed	1 / 548 (0.18%)	2 / 554 (0.36%)	
occurrences causally related to treatment / all	0 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Groin pain			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemarthrosis			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc compression			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscular weakness			

subjects affected / exposed	2 / 548 (0.36%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	2 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal pain			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteolysis			
subjects affected / exposed	0 / 548 (0.00%)	2 / 554 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain in extremity			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Abscess			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal abscess			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendicitis			
subjects affected / exposed	1 / 548 (0.18%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial infection			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis			

subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			
subjects affected / exposed	1 / 548 (0.18%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Complicated appendicitis			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile infection			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis			
subjects affected / exposed	2 / 548 (0.36%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	2 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
H1N1 influenza			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes zoster			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infection			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower respiratory tract infection			

subjects affected / exposed	2 / 548 (0.36%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Otitis media			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Perinephric abscess			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritonitis			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumocystis jirovecii pneumonia			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	6 / 548 (1.09%)	7 / 554 (1.26%)	
occurrences causally related to treatment / all	1 / 7	1 / 7	
deaths causally related to treatment / all	0 / 0	0 / 3	
Pneumonia aspiration			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia bacterial			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis			

subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis acute			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal abscess			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retroperitoneal abscess			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Salmonella sepsis			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	1 / 548 (0.18%)	3 / 554 (0.54%)	
occurrences causally related to treatment / all	0 / 1	2 / 3	
deaths causally related to treatment / all	0 / 1	1 / 1	
Septic shock			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Urinary tract infection			
subjects affected / exposed	1 / 548 (0.18%)	3 / 554 (0.54%)	
occurrences causally related to treatment / all	1 / 1	0 / 3	
deaths causally related to treatment / all	1 / 1	0 / 0	
Wound infection			

subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	2 / 548 (0.36%)	2 / 554 (0.36%)	
occurrences causally related to treatment / all	1 / 2	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dehydration			
subjects affected / exposed	11 / 548 (2.01%)	8 / 554 (1.44%)	
occurrences causally related to treatment / all	11 / 13	4 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrolyte imbalance			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperamylasaemia			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypercalcaemia			
subjects affected / exposed	1 / 548 (0.18%)	5 / 554 (0.90%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemia			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperkalaemia			
subjects affected / exposed	2 / 548 (0.36%)	2 / 554 (0.36%)	
occurrences causally related to treatment / all	1 / 2	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperlipasaemia			

subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperuricaemia			
subjects affected / exposed	2 / 548 (0.36%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	3 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypocalcaemia			
subjects affected / exposed	0 / 548 (0.00%)	2 / 554 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemia			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypokalaemia			
subjects affected / exposed	0 / 548 (0.00%)	1 / 554 (0.18%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			
subjects affected / exposed	7 / 548 (1.28%)	4 / 554 (0.72%)	
occurrences causally related to treatment / all	5 / 7	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypophosphataemia			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malnutrition			
subjects affected / exposed	1 / 548 (0.18%)	0 / 554 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Sunitinib	Pazopanib	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	535 / 548 (97.63%)	541 / 554 (97.65%)	
Vascular disorders			
Hypertension			
subjects affected / exposed	220 / 548 (40.15%)	256 / 554 (46.21%)	
occurrences (all)	291	314	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	58 / 548 (10.58%)	47 / 554 (8.48%)	
occurrences (all)	104	91	
Chills			
subjects affected / exposed	43 / 548 (7.85%)	15 / 554 (2.71%)	
occurrences (all)	51	15	
Face oedema			
subjects affected / exposed	40 / 548 (7.30%)	12 / 554 (2.17%)	
occurrences (all)	67	12	
Fatigue			
subjects affected / exposed	342 / 548 (62.41%)	305 / 554 (55.05%)	
occurrences (all)	649	392	
Mucosal inflammation			
subjects affected / exposed	141 / 548 (25.73%)	62 / 554 (11.19%)	
occurrences (all)	249	73	
Oedema			
subjects affected / exposed	37 / 548 (6.75%)	15 / 554 (2.71%)	
occurrences (all)	45	16	
Oedema peripheral			
subjects affected / exposed	86 / 548 (15.69%)	58 / 554 (10.47%)	
occurrences (all)	123	71	
Pyrexia			
subjects affected / exposed	77 / 548 (14.05%)	47 / 554 (8.48%)	
occurrences (all)	107	58	
Respiratory, thoracic and mediastinal disorders			

Cough			
subjects affected / exposed	105 / 548 (19.16%)	86 / 554 (15.52%)	
occurrences (all)	128	113	
Dyspnoea			
subjects affected / exposed	92 / 548 (16.79%)	79 / 554 (14.26%)	
occurrences (all)	107	95	
Dysphonia			
subjects affected / exposed	12 / 548 (2.19%)	42 / 554 (7.58%)	
occurrences (all)	12	47	
Epistaxis			
subjects affected / exposed	96 / 548 (17.52%)	49 / 554 (8.84%)	
occurrences (all)	155	65	
Oropharyngeal pain			
subjects affected / exposed	54 / 548 (9.85%)	39 / 554 (7.04%)	
occurrences (all)	67	41	
Psychiatric disorders			
Insomnia			
subjects affected / exposed	61 / 548 (11.13%)	58 / 554 (10.47%)	
occurrences (all)	63	59	
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	93 / 548 (16.97%)	143 / 554 (25.81%)	
occurrences (all)	134	176	
Amylase increased			
subjects affected / exposed	24 / 548 (4.38%)	39 / 554 (7.04%)	
occurrences (all)	48	54	
Aspartate aminotransferase increased			
subjects affected / exposed	96 / 548 (17.52%)	128 / 554 (23.10%)	
occurrences (all)	174	164	
Blood alkaline phosphatase increased			
subjects affected / exposed	30 / 548 (5.47%)	40 / 554 (7.22%)	
occurrences (all)	46	41	
Blood bilirubin increased			
subjects affected / exposed	35 / 548 (6.39%)	51 / 554 (9.21%)	
occurrences (all)	71	82	
Blood creatinine increased			

subjects affected / exposed	85 / 548 (15.51%)	52 / 554 (9.39%)	
occurrences (all)	202	98	
Blood lactate dehydrogenase increased			
subjects affected / exposed	60 / 548 (10.95%)	40 / 554 (7.22%)	
occurrences (all)	179	64	
Blood thyroid stimulating hormone increased			
subjects affected / exposed	64 / 548 (11.68%)	33 / 554 (5.96%)	
occurrences (all)	117	45	
Blood triglycerides increased			
subjects affected / exposed	35 / 548 (6.39%)	21 / 554 (3.79%)	
occurrences (all)	61	42	
Haemoglobin decreased			
subjects affected / exposed	75 / 548 (13.69%)	34 / 554 (6.14%)	
occurrences (all)	190	47	
Lipase increased			
subjects affected / exposed	32 / 548 (5.84%)	43 / 554 (7.76%)	
occurrences (all)	53	66	
Neutrophil count decreased			
subjects affected / exposed	60 / 548 (10.95%)	23 / 554 (4.15%)	
occurrences (all)	144	48	
Platelet count decreased			
subjects affected / exposed	97 / 548 (17.70%)	36 / 554 (6.50%)	
occurrences (all)	262	68	
Weight decreased			
subjects affected / exposed	33 / 548 (6.02%)	86 / 554 (15.52%)	
occurrences (all)	35	99	
White blood cell count decreased			
subjects affected / exposed	74 / 548 (13.50%)	31 / 554 (5.60%)	
occurrences (all)	168	55	
Nervous system disorders			
Dizziness			
subjects affected / exposed	82 / 548 (14.96%)	71 / 554 (12.82%)	
occurrences (all)	105	87	
Dysgeusia			

subjects affected / exposed occurrences (all)	58 / 548 (10.58%) 78	49 / 554 (8.84%) 58	
Taste disorder subjects affected / exposed occurrences (all)	145 / 548 (26.46%) 262	99 / 554 (17.87%) 106	
Headache subjects affected / exposed occurrences (all)	122 / 548 (22.26%) 179	124 / 554 (22.38%) 159	
Blood and lymphatic system disorders			
Anaemia subjects affected / exposed occurrences (all)	99 / 548 (18.07%) 160	36 / 554 (6.50%) 49	
Leukopenia subjects affected / exposed occurrences (all)	100 / 548 (18.25%) 250	51 / 554 (9.21%) 114	
Neutropenia subjects affected / exposed occurrences (all)	147 / 548 (26.82%) 383	60 / 554 (10.83%) 121	
Thrombocytopenia subjects affected / exposed occurrences (all)	180 / 548 (32.85%) 496	56 / 554 (10.11%) 118	
Eye disorders			
Eyelid oedema subjects affected / exposed occurrences (all)	39 / 548 (7.12%) 92	18 / 554 (3.25%) 32	
Gastrointestinal disorders			
Abdominal discomfort subjects affected / exposed occurrences (all)	33 / 548 (6.02%) 38	24 / 554 (4.33%) 32	
Abdominal distension subjects affected / exposed occurrences (all)	27 / 548 (4.93%) 32	34 / 554 (6.14%) 35	
Abdominal pain subjects affected / exposed occurrences (all)	74 / 548 (13.50%) 108	72 / 554 (13.00%) 86	
Abdominal pain upper			

subjects affected / exposed	49 / 548 (8.94%)	69 / 554 (12.45%)
occurrences (all)	63	89
Constipation		
subjects affected / exposed	133 / 548 (24.27%)	97 / 554 (17.51%)
occurrences (all)	189	112
Diarrhoea		
subjects affected / exposed	312 / 548 (56.93%)	349 / 554 (63.00%)
occurrences (all)	864	752
Dry mouth		
subjects affected / exposed	29 / 548 (5.29%)	26 / 554 (4.69%)
occurrences (all)	32	29
Dyspepsia		
subjects affected / exposed	135 / 548 (24.64%)	78 / 554 (14.08%)
occurrences (all)	209	93
Flatulence		
subjects affected / exposed	15 / 548 (2.74%)	32 / 554 (5.78%)
occurrences (all)	20	37
Mouth ulceration		
subjects affected / exposed	35 / 548 (6.39%)	22 / 554 (3.97%)
occurrences (all)	52	28
Gastrooesophageal reflux disease		
subjects affected / exposed	55 / 548 (10.04%)	19 / 554 (3.43%)
occurrences (all)	69	19
Nausea		
subjects affected / exposed	253 / 548 (46.17%)	248 / 554 (44.77%)
occurrences (all)	480	399
Oral pain		
subjects affected / exposed	28 / 548 (5.11%)	12 / 554 (2.17%)
occurrences (all)	44	14
Stomatitis		
subjects affected / exposed	154 / 548 (28.10%)	78 / 554 (14.08%)
occurrences (all)	303	99
Vomiting		
subjects affected / exposed	148 / 548 (27.01%)	158 / 554 (28.52%)
occurrences (all)	326	303
Skin and subcutaneous tissue disorders		

Alopecia			
subjects affected / exposed	45 / 548 (8.21%)	77 / 554 (13.90%)	
occurrences (all)	46	83	
Dry skin			
subjects affected / exposed	47 / 548 (8.58%)	44 / 554 (7.94%)	
occurrences (all)	53	53	
Hair colour changes			
subjects affected / exposed	54 / 548 (9.85%)	168 / 554 (30.32%)	
occurrences (all)	59	178	
Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	275 / 548 (50.18%)	163 / 554 (29.42%)	
occurrences (all)	615	248	
Pruritus			
subjects affected / exposed	45 / 548 (8.21%)	23 / 554 (4.15%)	
occurrences (all)	57	29	
Rash			
subjects affected / exposed	126 / 548 (22.99%)	95 / 554 (17.15%)	
occurrences (all)	201	143	
Yellow skin			
subjects affected / exposed	93 / 548 (16.97%)	4 / 554 (0.72%)	
occurrences (all)	151	5	
Renal and urinary disorders			
Haematuria			
subjects affected / exposed	28 / 548 (5.11%)	24 / 554 (4.33%)	
occurrences (all)	41	29	
Proteinuria			
subjects affected / exposed	76 / 548 (13.87%)	99 / 554 (17.87%)	
occurrences (all)	153	148	
Endocrine disorders			
Hyperthyroidism			
subjects affected / exposed	29 / 548 (5.29%)	7 / 554 (1.26%)	
occurrences (all)	31	7	
Hypothyroidism			
subjects affected / exposed	138 / 548 (25.18%)	71 / 554 (12.82%)	
occurrences (all)	173	74	
Musculoskeletal and connective tissue disorders			

Arthralgia			
subjects affected / exposed	82 / 548 (14.96%)	98 / 554 (17.69%)	
occurrences (all)	116	133	
Back pain			
subjects affected / exposed	89 / 548 (16.24%)	91 / 554 (16.43%)	
occurrences (all)	136	110	
Flank pain			
subjects affected / exposed	30 / 548 (5.47%)	14 / 554 (2.53%)	
occurrences (all)	40	18	
Muscle spasms			
subjects affected / exposed	23 / 548 (4.20%)	38 / 554 (6.86%)	
occurrences (all)	31	50	
Myalgia			
subjects affected / exposed	37 / 548 (6.75%)	34 / 554 (6.14%)	
occurrences (all)	44	39	
Pain in extremity			
subjects affected / exposed	93 / 548 (16.97%)	70 / 554 (12.64%)	
occurrences (all)	135	82	
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	42 / 548 (7.66%)	46 / 554 (8.30%)	
occurrences (all)	65	77	
Upper respiratory tract infection			
subjects affected / exposed	34 / 548 (6.20%)	30 / 554 (5.42%)	
occurrences (all)	47	40	
Urinary tract infection			
subjects affected / exposed	29 / 548 (5.29%)	23 / 554 (4.15%)	
occurrences (all)	40	32	
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	203 / 548 (37.04%)	207 / 554 (37.36%)	
occurrences (all)	328	305	
Hyperglycaemia			
subjects affected / exposed	30 / 548 (5.47%)	16 / 554 (2.89%)	
occurrences (all)	40	24	
Hyponatraemia			

subjects affected / exposed	36 / 548 (6.57%)	22 / 554 (3.97%)	
occurrences (all)	52	34	
Hypophosphataemia			
subjects affected / exposed	32 / 548 (5.84%)	21 / 554 (3.79%)	
occurrences (all)	57	35	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
27 October 2008	Amendment 1: Country Specific Amendment for Japan to add pharmacokinetic sampling for subjects randomized to pazopanib
01 April 2009	Amendment 2: Updates to Inclusion/Exclusion criteria, dose modification guidelines for liver toxicity, concomitant medication, addition of pharmacogenetic sampling and Supplementary Quality of Life Questions.
15 June 2009	Amendment 3: Country Specific Amendment for China to permit using 12.5 mg capsules of sunitinib for 50 mg, 37.5 mg, and 25 mg dose levels.
25 March 2011	Amendment 4: Change to safety visit schedule to decrease number of visits after Cycle 9 from Day 28 and Day 42 per cycle, to Day 42 per cycle. Changes in Data Analysis section to sample size assumptions and inclusion of subjects from Study A2201 for the analysis of safety and efficacy.
17 May 2013	Amendment 5: Changes to allow subjects continued access to pazopanib or sunitinib therapy following the Treatment Phase (in the absence of unacceptable toxicity, disease progression, or subject withdrawal). Subject treatment and disease management was conducted as indicated by local standard of medical care. Subjects who had already discontinued study treatment and were in progressive disease follow-up or survival follow-up were considered as having completed the study. Frequency of clinic visits reduced. Collection of safety information reduced to SAEs, pregnancies, AEs leading to study treatment discontinuation or other AEs the investigator deems important to report, and all other reasons leading to study treatment discontinuation.
05 December 2017	Amendment 6: Country specific amendment for China to permit use of pazopanib 200mg tablets (commercial supply) instead of 400mg tablets (clinical supply) in China.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

The full investigators lists and other Clinical Study Report appendices were not transferred over during the change in sponsorship from GlaxoSmithKline (GSK) to Novartis, the team could not confirm or quality control the investigator sites list.

Notes: